<DOC>
	<DOC>NCT00837265</DOC>
	<brief_summary>Determination of the effect of Neugranin on the duration and severity of severe neutropenia.</brief_summary>
	<brief_title>Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Breast cancer patients scheduled to receive the AT regimen (doxorubicin/ docetaxel). Subjects may have received no more than 1 prior chemotherapy regimen (including adjuvant therapy if given within the last 12 months).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Breast Cancer Supportive Care Neutropenia</keyword>
</DOC>